SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca PLC (NYSE:AZN)’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology ...
AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial ...
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of ...
Clinical Trials Arena on MSN
AstraZeneca’s cancer pipeline posts two wins and a loss
The UK-Swedish pharma giant has shared readouts from key portfolio assets such as Enhertu, Tagrisso and Etcamah.
Pfizer PFE faces a number of structural headwinds, ranging from patent expirations and declining COVID-19 revenues to pricing ...
Pfizer PFE and AstraZeneca AZN are global pharmaceutical leaders with a strong presence in oncology. For Pfizer, oncology is a major growth driver, contributing about 27% of total revenues. Beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results